Core Business

The purpose of Noxamet is the preclinical development of a new class of nitric oxide (NO) donors, the “metal-nonoates”, which have potential therapeutic activity towards many human pathologies, but mainly directed towards the cardiovascular field.


Metal-nonoates, in which the NO release properties of particular pro-drugs are modulated and enhanced after their complexation with metals, represent a significative innovation on respect to the drugs traditionally used as NO donors.


Those compounds, developed by Noxamet, are able to exploit the versatility of metal ions, as for ability of coordination of multifunctional binding molecules, of stereochemical flexibility, of variability of the ionic charge and chemical reactivity, in order to promote a controlled release of NO.